We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
+8.06%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$1.11T
AUM Growth
+$49.3B
Cap. Flow
-$2.91B
Cap. Flow %
-0.26%
Top 10 Hldgs %
27.74%
Holding
3,121
New
186
Increased
817
Reduced
1,825
Closed
148

Top Buys

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$18.7B
2
AAPL icon
Apple
AAPL
+$5.48B
3
NVDA icon
NVIDIA
NVDA
+$5.33B
4
TSLA icon
Tesla
TSLA
+$4.47B
5
MSFT icon
Microsoft
MSFT
+$2.15B

Top Sells

Rank Stock Value
1
V icon
Visa
V
+$4.26B
2
META icon
Meta Platforms (Facebook)
META
+$3.3B
3
MS icon
Morgan Stanley
MS
+$2.82B
4
GPN icon
Global Payments
GPN
+$2.43B
5
PYPL icon
PayPal
PYPL
+$2B

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Healthcare 16.09%
3 Consumer Discretionary 15.79%
4 Communication Services 12.38%
5 Financials 10.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ENVB icon
2826
Enveric Biosciences
ENVB
$6.24M
$129K ﹤0.01%
15
+9
+150% +$126K
INOD icon
2827
Innodata
INOD
$1.97B
$129K ﹤0.01%
21,800
KULR icon
2828
KULR Technology Group
KULR
$139M
$128K ﹤0.01%
+5,788
New +$134K
SUP
2829
DELISTED
Superior Industries International
SUP
$128K ﹤0.01%
28,600
OTIC
2830
DELISTED
Otonomy, Inc.
OTIC
$128K ﹤0.01%
61,400
IDN icon
2831
Intellicheck
IDN
$74.7M
$127K ﹤0.01%
27,400
-7,700
-22% -$52.9K
CTAQ
2832
DELISTED
Carney Technology Acquisition Corp. II Class A Common Stock
CTAQ
$127K ﹤0.01%
13,038
+2,661
+26% +$26.1K
CIA icon
2833
Citizens
CIA
$202M
$126K ﹤0.01%
23,685
-1,000
-4% -$6.12K
CRDF icon
2834
Cardiff Oncology
CRDF
$79.4M
$124K ﹤0.01%
+20,680
New +$123K
TCRT icon
2835
Alaunos Therapeutics
TCRT
$4.86M
$124K ﹤0.01%
760
-776
-51% -$171K
VVNT
2836
DELISTED
Vivint Smart Home, Inc. Class A Common Stock
VVNT
$124K ﹤0.01%
12,698
-12,638
-50% -$124K
OVID icon
2837
Ovid Therapeutics
OVID
$510M
$122K ﹤0.01%
37,961
XWEL icon
2838
XWELL
XWEL
$8.53M
$121K ﹤0.01%
3,005
SFR
2839
DELISTED
Appreciate Holdings, Inc. Class A Common Stock
SFR
$121K ﹤0.01%
+12,361
New +$121K
MTEM
2840
DELISTED
Molecular Templates, Inc.
MTEM
$121K ﹤0.01%
2,064
-80,666
-98% -$6.04M
GROW icon
2841
US Global Investors
GROW
$38.7M
$117K ﹤0.01%
26,700
YEXT icon
2842
Yext
YEXT
$580M
$115K ﹤0.01%
11,574
-19,149
-62% -$215K
PZN
2843
DELISTED
Pzena Investment Management, Inc. Class A
PZN
$115K ﹤0.01%
12,139
-200
-2% -$2.08K
PSFE icon
2844
Paysafe
PSFE
$367M
$112K ﹤0.01%
2,397
+377
+19% +$25.2K
VIPS icon
2845
Vipshop
VIPS
$6.79B
$112K ﹤0.01%
13,300
-239
-2% -$2.5K
TAL icon
2846
TAL Education Group
TAL
$6.43B
$111K ﹤0.01%
28,200
+12,400
+78% +$56K
NG icon
2847
NovaGold Resources
NG
$3.4B
$109K ﹤0.01%
15,904
-4,220
-21% -$30.8K
RMTI icon
2848
Rockwell Medical
RMTI
$29.1M
$109K ﹤0.01%
2,417
AP icon
2849
Ampco-Pittsburgh
AP
$193M
$108K ﹤0.01%
21,600
APT icon
2850
Alpha Pro Tech
APT
$55.3M
$108K ﹤0.01%
+18,100
New +$106K

Similar funds

T. Rowe Price Associates's Q4 2021 Portfolio in Review

As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
  • T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
  • T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
  • T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
  • T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
  • T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.